| content |
Efalizumab
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Efalizumab".
Efalizumab (Raptiva, Genentech, Merck Serono) is a medication used to treat psoriasis. As its name implies, it is a recombinant humanized monoclonal antibody that binds to CD11a and acts as an immunosuppressant. It is administered once weekly by subcutaneous injection.
It acts to inhibit white blood cell migration out of blood vessels into tissues.
|
Immunomodulators - Immunosuppressants - Immunosuppressive drugs (L04) |
|
| Extracellular |
|
|
CD3 ( Muromonab-CD3, Teplizumab, Visilizumab) · CD4 ( Keliximab, Zanolimumab) · CD11a ( Efalizumab) · CD20 ( Ocrelizumab, Pascolizumab) · CD23 ( Lumiliximab) · IL-2/CD25 ( Basiliximab, Daclizumab, Inolimomab) · CD40 ( Teneliximab) · CD62L/L-selectin ( Aselizumab) · CD147/Basigin ( Gavilimomab, Ziralimumab) · CD154 ( Ruplizumab)
BLyS (Belimumab) · Complement component 5 (Eculizumab) · CTLA-4 (Ipilimumab) · CAT (Metelimumab) · Immunoglobulin E (Omalizumab) · Integrin (Natalizumab) · Interleukin 5 (Mepolizumab) · Interleukin-6 receptor (Tocilizumab) · TNFs (Infliximab, Adalimumab, Certolizumab pegol, Afelimomab, Golimumab) · LFA-1 (Odulimomab)
other monoclonal: Atlizumab, Atorolimumab, Bertilimumab, Cedelizumab, Clenoliximab, Dorlimomab aritox, Dorlixizumab, Elsilimomab, Erlizumab, Faralimomab, Fontolizumab, Galiximab, Gantenerumab, Gomiliximab, Ibalizumab, Lebrilizumab, Lerdelimumab, Maslimomab, Morolimumab, Nerelimomab, Otelixizumab, Pexelizumab, Reslizumab, Rovelizumab, Siplizumab, Talizumab, Telimomab aritox, Toralizumab, Ustekinumab, Vapaliximab, Vepalimomab, Zolimomab aritox
Polyclonal: Anti-thymocyte globulin - Anti-lymphocyte globulin
|
|
|
|
|
|
|
|
|
|
|
| Intracellular |
|
|
|
Humanized monoclonal antibodies ("-zu-") |
|
| "-tuzu-" (tumor) |
Afutuzumab, Alemtuzumab, Bevacizumab/ Ranibizumab, Bivatuzumab mertansine, Cantuzumab mertansine, Citatuzumab bogatox, Dacetuzumab, Elotuzumab, Etaracizumab, Farletuzumab, Gemtuzumab ozogamicin, Inotuzumab ozogamicin, Labetuzumab, Lintuzumab, Matuzumab, Milatuzumab, Nimotuzumab, Pertuzumab, Sibrotuzumab, Sontuzumab, Tacatuzumab tetraxetan, Tigatuzumab, Trastuzumab, Tucotuzumab celmoleukin, Veltuzumab
|
|
| "-lizu-" (immune system) |
immunosuppressive: Aselizumab, Atlizumab, Apolizumab, Cedelizumab, Certolizumab pegol, Daclizumab, Eculizumab, Efalizumab, Epratuzumab, Erlizumab, Fontolizumab, Lebrilizumab, Mepolizumab, Natalizumab, Ocrelizumab, Omalizumab, Pascolizumab, Pexelizumab, Reslizumab, Rovelizumab, Ruplizumab, Siplizumab, Talizumab, Teplizumab, Tocilizumab, Toralizumab, Vedolizumab, Visilizumab
non-immunosuppressive: Ibalizumab
|
|
| "-bazu-" (bacterial) |
|
|
| "-cizu-" (cardiovascular) |
|
|
| "-nezu-"/"-neuzu-" (nervous system) |
|
|
| "-toxazu-" (toxin as target) |
|
|
| "-vizu-" (viral infections) |
|
|
|
© jGames.co.uk 2007 (some content from Wikipedia under GDL )
!-- ValueClick Media 468x60 and 728x90 Banner CODE for jgames.co.uk -->
|
